Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26530393 | 0.92 | HDAC6 (0.44) | HDAC6MAPTHDAC1 | |
| SCHEMBL26126161 | 0.92 | HDAC6 (0.50) | HDAC6NPC1RAB9AHDAC1 | |
| SCHEMBL26530388 | 0.89 | HDAC6 (0.46) | HDAC6 | |
| SCHEMBL26530566 | 0.87 | HDAC6 (0.46) | HDAC6HDAC1 | |
| SCHEMBL26530457 | 0.86 | HDAC6 (0.43) | HDAC6 | |
| SCHEMBL26530383 | 0.85 | HDAC6 (0.46) | HDAC6HDAC1 | |
| SCHEMBL26530481 | 0.84 | HDAC6 (0.43) | HDAC6HDAC1 | |
| SCHEMBL26530404 | 0.84 | HDAC6 (0.46) | HDAC6NPC1RAB9A | |
| SCHEMBL26124305 | 0.83 | HDAC6 (0.50) | HDAC6HDAC1 | |
| SCHEMBL26530551 | 0.81 | HDAC6 (0.45) | HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | HDAC6 1/4885NPC1 2177/4885RAB9A 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.